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EVALUATION OF HUMAN EPIDIDYMAL SECRETORY PROTEIN E4 (HE4) 
FOR MONITORING FOR OVARIAN CANCER RECURRENCE  
 
K. Chan, K.F. Tam, H. Ngan  
Obstetrics and Gynaecology, University of Hong Kong, Hong Kong, Hong Kong S.A.R.  
 
Introduction: Serum HE4, a new biomarker for ovarian cancer, was shown to have a 
better sensitivity for detecting ovarian cancer compared to Ca 125, especially in early 
disease. In this study, we measured the HE4 levels in patients who had relapsed ovarian 
cancer in an attempt to elucidate its role in disease monitoring and recurrence detection.  
Methods: HE4 levels were measured at pre-treatment, immediately post treatment 
(remission), just prior to diagnosis of recurrence and at recurrence using a commercial 
available ELISA kit in women with ovarian cancer recurrence. The results were 
compared with Ca 125 levels. Levels of more than 70 pmol/L and 35 u/ml were 
considered raised for HE4 and Ca 125 respectively. Chi square test was used to detect 
difference between groups.  
Results: 67 patients with saved sera available at recurrence were included in the study. 
At pretreatment 59 ( 88% ) have raised Ca 125 compared to 63.6% with raised HE4. The 
sensitivity for recurrence detection was 92.5% ( 62/67 ) and 61.2% ( 41/67 ) for HE4 
( p=0.004) respectively. Specificity of HE4 and Ca125, based on the levels when there 
was no evidence of disease were 82.1% for HE4 versus 98% for Ca 125. 12 (24.4 %) 
patients had raised HE4 before the rise of Ca 125, whereas 6 ( 14.3%) had raised Ca 125 
first.  
Conclusion: HE4 reflected in the disease process in women with ovarian recurrence but 
has a lower sensitivity than Ca 125 in recurrence detection. 
